D.C. Diagnosis

D.C. Diagnosis Sarah Owermohle

STAT Plus: Will a government shutdown stall Medicare drug price negotiations?

D.C. Diagnosis Rachel Cohrs Zhang

Senate HELP on collision course

D.C. Diagnosis Sarah Owermohle

STAT Plus: Is there a path forward for PEPFAR?

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: A new House health package & hospitals’ new site-neutral talking points

D.C. Diagnosis Sarah Owermohle

Setting the September calendar in health care

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Abortion policy in the spotlight, DeSantis’ importation showdown, and new price hike analysis

D.C. Diagnosis Sarah Owermohle

What RFK Jr.’s popularity says about GOP health priorities, Lilly CEO’s big bet, and the looming cereal wars

D.C. Diagnosis Sarah Owermohle

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on

D.C. Diagnosis Rachel Cohrs Zhang

After nine months, an update on NIH’s long Covid research

Health Lev Facher

Biden administration unveils dashboard to track nonfatal drug overdoses

D.C. Diagnosis Sarah Owermohle

Health funding battles, a nutrition policy overhaul, and two CBD developments

D.C. Diagnosis Rachel Cohrs Zhang

It’s not looking good for Covid and monkeypox funding, problems ahead for PrEP, & the not-so-historic Juul settlement

D.C. Diagnosis Elissa Welle

Democrats’ TGIF moment, pathologists defend their turf, & Biogen’s back at the FDA’s doorstep

D.C. Diagnosis Edward Chen

A chaotic sprint to lower insulin prices and AIDS activists go after Biden on monkeypox

D.C. Diagnosis Rachel Cohrs Zhang

The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill

D.C. Diagnosis Nicholas Florko

PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama

D.C. Diagnosis Rachel Cohrs Zhang

The unlikely crusader who’s winning the fight to lower hospital prices

D.C. Diagnosis Lev Facher

The Senate health committee finally marks up its user fee bill

D.C. Diagnosis Rachel Cohrs Zhang

California senators advance three bills meant to crack down on health insurers

D.C. Diagnosis Nicholas Florko

A no good, very bad week for the FDA

D.C. Diagnosis Rachel Cohrs Zhang

AstraZeneca’s ambitious vaccine dreams are finally, officially dead

D.C. Diagnosis Nicholas Florko

As Congress takes up FDA oversight of dietary supplements, a lobbying showdown looms

D.C. Diagnosis Nicholas Florko

Pharma showers John Thune with campaign cash

D.C. Diagnosis Nicholas Florko

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

D.C. Diagnosis Nicholas Florko

The FDA’s ban on menthol in cigarettes clears a major regulatory hurdle

D.C. Diagnosis Nicholas Florko

Biogen’s head-scratching new lobbyist hire

D.C. Diagnosis Nicholas Florko

The next battle in the never-ending war over Aduhelm

D.C. Diagnosis Nicholas Florko

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA